Literature DB >> 11848149

The cost-effectiveness of residential radon remediation programmes: assumptions about benefits stream profiles over time.

Christine A Kennedy1, Alastair M Gray, Antony R Denman, Paul S Phillips.   

Abstract

A recent cost-effectiveness analysis of a residential radon remediation programme considered and highlighted many areas of uncertainty in the parameters chosen for the analysis. One assumption not challenged in the study was the benefits stream profile adopted. There are several different ways of loading the benefits in terms of life years into the cost-effectiveness model and several of these are explored and the results are reported in this study. The benefits profile depends upon the lead-time to cancer manifestation post environmental carcinogen (radon) exposure. The literature reviewed suggests that there are many options for loading benefits to radon-induced lung cancer prevention programmes. In this study, the alternative benefits stream profiles are explored and their implications for the cost-effectiveness ratio are examined. Adopting different benefits stream profiles to the model results in a range of cost-effectiveness ratios from 14912.90 pounds per life year gained to 52416.27 pounds per life year gained. The preferred model is reported where the life years gained are assumed to be equally distributed over the last 15 years of the 40-year time horizon of the analysis (Y25-40) and the corresponding cost-effectiveness ratio is 37,943 pounds per life year gained.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11848149     DOI: 10.1016/s0265-931x(01)00031-5

Source DB:  PubMed          Journal:  J Environ Radioact        ISSN: 0265-931X            Impact factor:   2.674


  2 in total

1.  Effects of α-Particle Radiation on MicroRNA Responses in Human Cell-Lines.

Authors:  Vinita Chauhan; Matthew Howland; Ruth Wilkins
Journal:  Open Biochem J       Date:  2012-03-19

2.  Home energy efficiency and radon related risk of lung cancer: modelling study.

Authors:  James Milner; Clive Shrubsole; Payel Das; Benjamin Jones; Ian Ridley; Zaid Chalabi; Ian Hamilton; Ben Armstrong; Michael Davies; Paul Wilkinson
Journal:  BMJ       Date:  2014-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.